Literature DB >> 15916968

Activin and activin receptor expression changes in liver regeneration in rat.

Kazuhito Takamura1, Kunihiro Tsuchida, Hidenori Miyake, Seiki Tashiro, Hiromu Sugino.   

Abstract

BACKGROUND: This study aimed to investigate regulatory mechanisms of hepatocyte proliferation by comparing liver regeneration of the remnant lobe after 70% partial hepatectomy (PH) and portal vein branch ligation (PBL) in rat.
METHODS: Expressions of activins betaA, betaC, and betaE and their receptors were investigated after PH and PBL. The proliferating cell nuclear antigen (PCNA) labeling index was used to monitor hepatocyte proliferation.
RESULTS: The PCNA labeling index in the regenerative lobe of PBL rats reached a peak at 48 h, a delay of 24 h compared with the remnant lobe in PH rats. In the postoperative early stage, the expression of activin betaA, betaC, and betaE mRNAs was stronger in PBL than PH. At 72 h the expression of activin receptor type IIA mRNA reached a peak in PH but was significantly lower in PBL.
CONCLUSIONS: Hepatocyte proliferation, and the regulated expression of activins and their receptors, differs during liver regeneration after PH and PBL in the rat. Thus, regulation of activin signaling through receptors is one of the factors determining liver regeneration after PH and PBL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916968     DOI: 10.1016/j.jss.2005.01.002

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  20 in total

Review 1.  Mechanisms of hepatic regeneration following portal vein embolization and partial hepatectomy: a review.

Authors:  Y Yokoyama; M Nagino; Y Nimura
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 2.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

3.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

4.  BMP4 is a novel paracrine inhibitor of liver regeneration.

Authors:  Nhue Do; Rong Zhao; Kevin Ray; Karen Ho; Martin Dib; Xianghui Ren; Paula Kuzontkoski; Ernest Terwilliger; Seth J Karp
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-27       Impact factor: 4.052

5.  Liver regeneration and the atrophy-hypertrophy complex.

Authors:  Robin D Kim; Jae Sung Kim; Go Watanabe; Dagmara Mohuczy; Kevin E Behrns
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

6.  Perioperative hepatocyte growth factor (HGF) infusions improve hepatic regeneration following portal branch ligation (PBL) in rodents.

Authors:  Christopher W Mangieri; Jason C McCartt; Matthew A Strode; John E Lowry; Prasad M Balakrishna
Journal:  Surg Endosc       Date:  2016-10-17       Impact factor: 4.584

7.  Rat activin-betaE mRNA expression during development and in acute and chronic liver injury.

Authors:  Elspeth J Gold; Marcel A Monaghan; Jean S Fleming
Journal:  J Mol Genet Med       Date:  2006-04-12

8.  Tob1 is a constitutively expressed repressor of liver regeneration.

Authors:  Karen J Ho; Nhue L Do; Hasan H Otu; Martin J Dib; Xianghui Ren; Keiichi Enjyoji; Simon C Robson; Ernest F Terwilliger; Seth J Karp
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

Review 9.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa1-6 cells and its relationship with collagen type IV.

Authors:  Hong-Jun Zhang; Gui-Xiang Tai; Jing Zhou; Di Ma; Zhong-Hui Liu
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.